| Dr Benjamin Jason Rogoway, MD | |
|
505 Ne 87th Ave, Building B, Suite 301, Vancouver, WA 98664-1989 | |
| (360) 514-1854 | |
| Not Available |
| Full Name | Dr Benjamin Jason Rogoway |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 20 Years |
| Location | 505 Ne 87th Ave, Vancouver, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336363290 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0102X | Surgery - Surgical Critical Care | MD60278948 (Washington) | Primary |
| 208600000X | Surgery | MD60278948 (Washington) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Desert Medical Center | Mesa, AZ | Hospital |
| Banner Baywood Medical Center | Mesa, AZ | Hospital |
| Banner Gateway Medical Center | Gilbert, AZ | Hospital |
| Banner Goldfield Medical Center | Apache junction, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arizona Advanced Surgery Llc | 0547690166 | 64 |
News Archive
"By tackling cost at the same time as access," the Obama administration and congressional lawmakers "have made their political challenge more difficult," the New York Times reports.
Cancer is among the leading causes of death worldwide> There were approximately 14m new cases diagnosed and 8.2m cancer related deaths in 2012. This figure is expected to rise of about 70% over the next two decades.
Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.
The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division.
› Verified 4 days ago
| Entity Name | Arizona Advanced Surgery Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346880838 PECOS PAC ID: 0547690166 Enrollment ID: O20200423000406 |
News Archive
"By tackling cost at the same time as access," the Obama administration and congressional lawmakers "have made their political challenge more difficult," the New York Times reports.
Cancer is among the leading causes of death worldwide> There were approximately 14m new cases diagnosed and 8.2m cancer related deaths in 2012. This figure is expected to rise of about 70% over the next two decades.
Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.
The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division.
› Verified 4 days ago
| Entity Name | Acute Surgical Care Specialists Of Arizona Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235704669 PECOS PAC ID: 6103222476 Enrollment ID: O20210913000386 |
News Archive
"By tackling cost at the same time as access," the Obama administration and congressional lawmakers "have made their political challenge more difficult," the New York Times reports.
Cancer is among the leading causes of death worldwide> There were approximately 14m new cases diagnosed and 8.2m cancer related deaths in 2012. This figure is expected to rise of about 70% over the next two decades.
Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.
The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Benjamin Jason Rogoway, MD 505 Ne 87th Ave, Building B, Suite 301, Vancouver, WA 98664-1989 Ph: (360) 514-1854 | Dr Benjamin Jason Rogoway, MD 505 Ne 87th Ave, Building B, Suite 301, Vancouver, WA 98664-1989 Ph: (360) 514-1854 |
News Archive
"By tackling cost at the same time as access," the Obama administration and congressional lawmakers "have made their political challenge more difficult," the New York Times reports.
Cancer is among the leading causes of death worldwide> There were approximately 14m new cases diagnosed and 8.2m cancer related deaths in 2012. This figure is expected to rise of about 70% over the next two decades.
Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.
The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division.
› Verified 4 days ago
Andrew Edward Glover, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 700 Ne 87th Ave, Vancouver, WA 98664 Phone: 360-397-3936 | |
Louis Moreau, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 700 Ne 87th Ave, Vancouver, WA 98664 Phone: 360-397-1500 Fax: 360-604-1771 | |
Michael John O'toole, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2211 E Mill Plain Blvd, Vancouver, WA 98661 Phone: 360-619-4244 | |
Toni Lucille Storm, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 210 Se 136th Ave, Vancouver, WA 98684 Phone: 360-944-9889 Fax: 360-944-9686 | |
Jane Namkung, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 13712 Ne 10th Ave, Vancouver, WA 98685 Phone: 360-823-0860 | |
Dr. James Bernard Kilway Ii, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 8614 E Mill Plain Blvd, Suite #201, Vancouver, WA 98664 Phone: 360-254-9991 Fax: 360-254-9997 | |
Dr. Kathleen Alison Dunham, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1498 Se Tech Center Pl, Suite 240, Vancouver, WA 98683 Phone: 360-597-1300 |